Bill > HR3546

This bill, titled the "Prescription Drug Price Relief Act of 2025," aims to reduce prescription drug prices in the United States by implementing a comprehensive strategy to address excessively priced medications. The bill establishes a process for the Secretary of Health and Human Services to review brand name drugs and determine if their prices are excessive by comparing them to prices in five reference countries (Canada, United Kingdom, Germany, France, and Japan). If a drug is found to have an excessive price, the government will waive or void any existing drug monopolies and grant open, non-exclusive licenses to other manufacturers to produce the drug. The bill requires drug manufacturers to submit detailed annual reports about their drug pricing, research and development costs, and marketing expenses. Additionally, it creates a public database to track excessive drug pricing and authorizes the government to take civil action against manufacturers who increase drug prices after being identified as excessively priced. The legislation also prohibits anticompetitive behavior and sets up a system where generic or biosimilar drug manufacturers can obtain licenses to produce expensive drugs, paying a reasonable royalty to the original manufacturer. The ultimate goal is to make prescription drugs more affordable by introducing competition and transparency into the pharmaceutical market.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/3546/all-info